Physician profile
Zeev Nemirovsky
NPI 1679015747
$19,094.30
in general payments reported to CMS, 2019-2025
35 companies · $4,705 in 2025
The $4,705 reported for 2025 was more than what 98% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,028 · 2022: $3,665 · 2023: $4,208 · 2024: $3,488 · 2025: $4,705.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,293.52 |
| Education | $108.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,684.62 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,015.88 | 2021-2025 | Xifaxan, Relistor, Trulance |
| Janssen Biotech, INC. | $1,545.77 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Celgene Corporation | $1,386.72 | 2021-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $1,267.71 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Pfizer INC. | $922.85 | 2021-2025 | |
| Gilead Sciences, INC. | $750.86 | 2021-2025 | |
| Madrigal Pharmaceuticals | $576.19 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $573.86 | 2023-2025 | |
| Ardelyx, INC. | $555.17 | 2022-2025 | Ibsrela |
| Redhill Biopharma INC. | $486.85 | 2021-2023 | |
| Amgen INC. | $448.32 | 2021-2023 | Amjevita, Avsola |
| Nestle Healthcare Nutrition INC. | $445.43 | 2021-2023 | |
| Aimmune Therapeutics, INC. | $382.67 | 2024-2025 | Zenpep, Vowst |
| Regeneron Healthcare Solutions, INC. | $287.31 | 2022-2024 | Dupixent |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $261.86 | 2021-2024 | Linzess |
| Intercept Pharmaceuticals, INC. | $203.09 | 2021-2025 | Ocaliva |
| Qol Medical, LLC | $169.63 | 2021-2025 | Sucraid, Sucraid |
| E.R. Squibb & Sons, L.L.C. | $140.92 | 2022-2023 | Zeposia |
| Ipsen Biopharmaceuticals, INC | $134.63 | 2024-2025 | Iqirvo |
| Merck Sharp & Dohme LLC | $130.09 | 2021-2023 | Zinplava, Dificid |
| Braintree Laboratories, INC. | $129.11 | 2021-2024 | Sutab, Suflave |
| Lilly USA, LLC | $84.16 | 2024-2025 | Omvoh |
| Fresenius Kabi USA, LLC | $82.15 | 2023-2024 | Idacio |
| Organon LLC | $79.58 | 2021-2025 | Renflexis, Hadlima |
| Phathom Pharmaceuticals, INC. | $79.16 | 2024-2025 | Voquezna |
| Daiichi Sankyo INC. | $51.63 | 2021-2022 | |
| Celltrion USA INC. | $46.55 | 2024-2025 | Vegzelma, Zymfentra |
| Ferring Pharmaceuticals INC. | $43.55 | 2021-2022 | |
| Pharmacosmos Therapeutics INC. | $37.26 | 2021 | |
| Alnylam Pharmaceuticals INC. | $34.73 | 2023-2024 | Givlaari |
| Novo Nordisk INC | $20.76 | 2025 | Wegovy |
| Endogastric Solutions, INC | $13.94 | 2024 | Esophyx |
| Evoke Pharma, INC. | $12.05 | 2021 | |
| Janssen Pharmaceuticals, INC | $9.24 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zeev Nemirovsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.